sorafenib has been researched along with pf-562,271 in 5 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (pf-562,271) | Trials (pf-562,271) | Recent Studies (post-2010) (pf-562,271) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 28 | 0 | 25 |
| Protein | Taxonomy | sorafenib (IC50) | pf-562,271 (IC50) |
|---|---|---|---|
| Chain A, Focal adhesion kinase 1 | Homo sapiens (human) | 0.0015 | |
| Androgen receptor | Rattus norvegicus (Norway rat) | 0.014 | |
| Focal adhesion kinase 1 | Homo sapiens (human) | 0.0014 | |
| Protein-tyrosine kinase 2-beta | Homo sapiens (human) | 0.0104 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 2 (40.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hajduk, PJ; Johnson, EF; Kifle, L; Merta, PJ; Metz, JT; Soni, NB | 1 |
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Aiche, S; Bassermann, F; Becker, W; Canevari, G; Casale, E; Depaolini, SR; Ehrlich, HC; Felder, ER; Feuchtinger, A; Garz, AK; Gohlke, BO; Götze, K; Greif, PA; Hahne, H; Heinzlmeir, S; Helm, D; Huenges, J; Jeremias, I; Kayser, G; Klaeger, S; Koch, H; Koenig, PA; Kramer, K; Kuster, B; Médard, G; Meng, C; Petzoldt, S; Polzer, H; Preissner, R; Qiao, H; Reinecke, M; Reiter, K; Rueckert, L; Ruland, J; Ruprecht, B; Schlegl, J; Schmidt, T; Schneider, S; Schoof, M; Spiekermann, K; Tõnisson, N; Vick, B; Vooder, T; Walch, A; Wilhelm, M; Wu, Z; Zecha, J; Zolg, DP | 1 |
| Gong, C; Huang, J; Liu, Y; Tan, H; Zhang, J; Zhang, Q | 1 |
| Cho, H; Choi, HG; Jeon, E; Kim, ND; Kim, S; Kim, Y; Kwon, NH; Lee, J; Moon, Y; Ryu, S; Shin, I; Sim, T; Song, C; Yoon, H | 1 |
5 other study(ies) available for sorafenib and pf-562,271
| Article | Year |
|---|---|
Navigating the kinome.
Topics: Drug Design; Pharmacogenetics; Protein Kinases; Proteome; Systems Biology | 2011 |
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
The target landscape of clinical kinase drugs.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Xenograft Model Antitumor Assays | 2017 |
Synthesis and evaluation of FAK inhibitors with a 5-fluoro-7H-pyrrolo[2,3-d]pyrimidine scaffold as anti-hepatocellular carcinoma agents.
Topics: Animals; Binding Sites; Carcinoma, Hepatocellular; Catalytic Domain; Cell Line, Tumor; Cell Proliferation; Focal Adhesion Protein-Tyrosine Kinases; Half-Life; Humans; Liver Neoplasms; Male; Mice; Mice, Nude; Molecular Docking Simulation; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Small Molecule Libraries; Structure-Activity Relationship; Transplantation, Heterologous | 2021 |
Identification of Thieno[3,2-
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Drug Screening Assays, Antitumor; Female; fms-Like Tyrosine Kinase 3; Focal Adhesion Kinase 1; Humans; Mice, Inbred BALB C; Mice, Nude; Molecular Docking Simulation; Molecular Structure; Neoplasm Metastasis; Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Pyrimidines; Structure-Activity Relationship; Thiophenes; Xenograft Model Antitumor Assays | 2021 |